Philanthropic Funding Enables New Test to Detect Parkinson’s Before Symptoms Appear

A study backed by the Sergey Brin Family Foundation and the Michael J. Fox Foundation validated the αSyn-SAA assay, which detects misfolded alpha-synuclein seeds in cerebrospinal fluid. In a trial of more than 1,100 participants, the test distinguished diagnosed Parkinson’s patients from healthy controls with 88% sensitivity and 96% specificity, and performed even better in classic cases. Importantly, the assay returned positive results in individuals carrying genetic or clinical risk factors before any tremor or stiffness appeared.

The findings, reported in The Lancet Neurology, led the Parkinson’s Progression Markers Initiative to rename itself the Parkinson’s Precision Medicine Initiative, shifting focus toward early diagnosis and targeted therapies. The long-term development relied on extensive private philanthropy, including over $800 million from the Michael J. Fox Foundation over 15 years. Researchers Andrew Siderowf and Luis Concha co-led the effort, highlighting the test’s potential to reshape drug development and personalize treatment.